(2) | (47) | " (5) | # (2) | $ (1) | 0 (43) | 1 (528) | 2 (598) | 3 (345) | 4 (27) | 5 (20) | 6 (14) | 7 (6) | 8 (3) | 9 (4) | < (49) | A (334) | B (70) | C (269) | D (140) | E (194) | F (157) | G (461) | H (72) | I (178) | J (46) | K (71) | L (86) | M (209) | N (154) | O (62) | P (276) | Q (10) | R (114) | S (496) | T (559) | U (133) | V (38) | W (306) | X (9) | Y (15) | Z (8) |   (1) | Д (1) | П (1) | С (1) | إ (1) | ‘ (2) | “ (1)
Title Last update
32-7.3 CS Delegations Proposal [.pdf] Fri, 01/27/2023 - 03:08
32-7.4_crg_board_presentation.zip Mon, 01/30/2023 - 06:53
32-8.1_DRAFT TB REACH 3.0 Concept [.pdf] Fri, 01/27/2023 - 03:29
32-8.2 TBREACH Paper on artificial intelligence to read chest radiographs for TB detection [.pdf] Fri, 01/27/2023 - 03:30
32-8.3 Multi-Site Evaluation of Innovative Approaches to TB notification_TB REACH Wave 1_Plos One 2013 [.pdf] Fri, 01/27/2023 - 03:30
32-8.4 Health extension workers improve TB finding&outcome in Ethiopia BMJ 2018 [.pdf] Fri, 01/27/2023 - 03:31
32-8.5 Pragmatic approach to M&E interventions for improved TB detection_Methods Int Health 2014 [.pdf] Fri, 01/27/2023 - 03:31
32-8.6 Learning Evaluation of 3 CAR Algorithms Scientifc Reports 2019 [.pdf] Fri, 01/27/2023 - 03:32
32-8.7 Engaging the private sector in TB case detection Lancet ID 2012 [.pdf] Fri, 01/27/2023 - 03:32
32-8.8 TB REACH 3.0_Presentation [.pdf] Fri, 01/27/2023 - 03:33
32-9-1.1 STBP GDF Paediatric DRTB Initiative EB Pre-Read [.pdf] Fri, 01/27/2023 - 04:36
32-9-1.2 TPMAT 2019 June meeting highlights [.pdf] Fri, 01/27/2023 - 04:37
32-9-2.1 Stop TB GDF Medicines Dashboard [.pdf] Fri, 01/27/2023 - 04:39
32-9-2.2 Indicative lead-times for planning purposes for TB products [.pdf] Fri, 01/27/2023 - 04:39
32-9-2.3 Budgeting Prices for TB Medicines through Global Drug FacilitySTP [.pdf] Fri, 01/27/2023 - 04:40
32-9-2.4 REUTERS_New MDR-TB treatment cost for developing countries [.pdf] Fri, 01/27/2023 - 04:40
32-9-2.5.1 Stop TB GDF Medicines Catalog [.pdf] Fri, 01/27/2023 - 04:41
32-9-2.5.2 Stop TB Global Drug Facility Diagnostics Catalog [.pdf] Fri, 01/27/2023 - 04:41
32-9-2.6 GDF_Technical_Information_Note_TBLAM [.pdf] Fri, 01/27/2023 - 04:44
32-9-2.7 GDF_Technical_Information_Note_TBLAMP [.pdf] Fri, 01/27/2023 - 04:44
32-9-2.8 GDF_Technical_Information_Note_Xpert [.pdf] Fri, 01/27/2023 - 04:44
32-9-2.9 Model Service Level Agreement for Xpert Surcharges v1 [.pdf] Fri, 01/27/2023 - 04:45
32-9.1 Global Drug Facility_Presentation [.pdf] Fri, 01/27/2023 - 04:38
33-0.1 Virtual Guidance Note Wed, 01/25/2023 - 04:23
33-0.2 List of Documents Wed, 01/25/2023 - 04:23
33-0.3 List of Participants_20 November 2020 Wed, 01/25/2023 - 04:24
33-1.1 Draft Agenda 20Nov Wed, 01/25/2023 - 04:27
33-1.2 Report on Actions of DPs_32nd Board meeting Wed, 01/25/2023 - 04:28
33-10.1 Independent Review Findings Wed, 01/25/2023 - 05:01
33-10.2 PWC Staff Pulse Survey - Summary deck of topline findings Wed, 01/25/2023 - 05:01
33-10.3 STP Board Proposed Action Plan 112020 Wed, 01/25/2023 - 05:01
33-13.1 2020 Updated TB REACH 3.0 Concept Wed, 01/25/2023 - 05:07
33-13.2 Costing analysis for Wave 5 projects Wed, 01/25/2023 - 05:17
33-13.3 Perspectives on TB REACH in the Asia-Pacific Region Wed, 01/25/2023 - 05:17
33-13.4 Wave 9 Concept Note Wed, 01/25/2023 - 05:18
33-13.5 IDP screening for TB and HIV in Nigeria Wed, 01/25/2023 - 05:18